Hospira (HSP) Q3 2011 Earnings Call October 26, 2011 9:00 am ET Executives Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of Research & Development & Medical Affairs Karen King - Vice President Investor Relations Michael Michael Ball - Chief Executive Officer, Director and Member of Science, Technology & Quality Committee Analysts Gregory Hertz - Citigroup Inc, Research Division Robert M. Goldman - CL King & Associates, Inc. Gregory B. Gilbert - BofA Merrill Lynch, Research Division Frederick A. Wise - Leerink Swann LLC, Research Division Jessica Fye - JP Morgan Chase & Co, Research Division Jayson T. Bedford - Raymond James & Associates, Inc., Research Division Matthew Taylor - Barclays Capital, Research Division David H. Roman - Goldman Sachs Group Inc., Research Division Shibani Malhotra - RBC Capital Markets, LLC, Research Division Marshall Urist - Morgan Stanley, Research Division David G. Buck - Buckingham Research Group, Inc. Louise A. Chen - Collins Stewart LLC, Research Division PresentationOperator
Welcome to Hospira's Third Quarter 2011 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference. Karen King Thank you. Good morning, everyone, and welcome to our conference call and webcast regarding Hospira's financial results for the third quarter of 2011. Participating in today's call are Mike Ball, Chief Executive Officer of Hospira; Tom Werner, Senior Vice President of Finance and Chief Financial Officer; Sumant Ramachandra, Senior Vice President and Chief Scientific Officer, will also be joining us for Q&A.